Skip to main content

. 2015 Oct 21;26(12):2505. doi: 10.1093/annonc/mdv477

A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer

B H O'Neil ¹, A J Scott ², W W Ma ³, S J Cohen ⁴, L Leichman ⁵, D L Aisner ², A R Menter ⁶, M A Tejani ⁷, J K Cho ⁸, J Granfortuna ⁹, L Coveler ¹⁰, O O Olowokure ¹¹, J C Baranda ¹², M Cusnir ¹³, P Phillip ¹⁴, J Boles ¹⁵, R Nazemzadeh ¹⁶, M Rarick ¹⁷, D J Cohen ¹⁸, J Radford ¹⁹, L Fehrenbacher ²⁰, R Bajaj ²¹, V Bathini ²², P Fanta ²³, J Berlin ²⁴, A J McRee ²⁵, R Maguire ²⁶, F Wilhelm ²⁶, M Maniar ²⁶, A Jimeno ², C L Gomes ²⁷, W A Messersmith ²

PMCID: PMC5266090 PMID: 26489442

Ann Oncol 2015; 26: 1923–1929 (doi: 10.1093/annonc/mdv264)

In the original article, author L. Leichman was omitted.

The corrected authors and affiliations are as above.

ACTIONS

RESOURCES